Suppr超能文献

2202名具有10年移植肾功能的肾移植受者:接下来会发生什么?

2202 kidney transplant recipients with 10 years of graft function: what happens next?

作者信息

Matas A J, Gillingham K J, Humar A, Kandaswamy R, Sutherland D E R, Payne W D, Dunn T B, Najarian J S

机构信息

Department of Surgery, University of Minnesota, Minneapolis, MN, USA.

出版信息

Am J Transplant. 2008 Nov;8(11):2410-9. doi: 10.1111/j.1600-6143.2008.02414.x.

Abstract

The ultimate goal of clinical transplantation is for the recipients to achieve long-term survival, with continuing graft function, that is equivalent to that of the age-matched general population. We studied subsequent outcome in kidney transplant recipients with 10 years of graft function. In all, 2202 kidney transplant recipients survived with graft function >10 years. For 10-year survivors, the actuarial 25-year patient survival rate for primary transplant living donor (LD) recipients was 57%; graft survival, 43%. For primary transplant deceased donor (DD) recipients, the actuarial 25-year patient survival rate was 39%; graft survival, 27%. The two major causes of late graft loss were death (with graft function) and chronic allograft nephropathy (tubular atrophy and interstitial fibrosis). The two major causes of death with function were cardiovascular disease (CVD) and malignancy. For nondiabetic recipients, the mean age at death with function from CVD was 54 +/- 13 years; for diabetic recipients, 53 +/- 7 years. By 20 years posttransplant, morbidity was common: >40% recipients had skin cancer (mean age for nondiabetic recipients, 53 +/- 13 years; for diabetics, 49 +/- 8 years), >10% had non-skin cancer (mean age for nondiabetic recipients, 53 +/- 16 years; for diabetics, 46 +/- 9 years), and >30% had CVD (mean age for nondiabetic recipients, 53 +/- 15 years; for diabetics, 47 +/- 9 years). We conclude that long-term transplant recipients have a high rate of morbidity and early mortality. As short-term results have improved, more focus is needed on long-term outcome.

摘要

临床移植的最终目标是让受者实现长期存活,并使移植器官持续发挥功能,达到与年龄匹配的普通人群相当的水平。我们研究了肾移植受者在移植器官功能达10年时的后续转归情况。共有2202例肾移植受者在移植器官功能大于10年的情况下存活。对于存活10年的患者,初次移植活体供肾(LD)受者的25年预期患者生存率为57%;移植器官生存率为43%。对于初次移植尸体供肾(DD)受者,25年预期患者生存率为39%;移植器官生存率为27%。移植器官晚期丢失的两个主要原因是死亡(移植器官仍有功能)和慢性移植肾肾病(肾小管萎缩和间质纤维化)。伴有功能的死亡的两个主要原因是心血管疾病(CVD)和恶性肿瘤。对于非糖尿病受者,因CVD伴有功能的死亡的平均年龄为54±13岁;对于糖尿病受者,为53±7岁。移植后20年时,发病率普遍较高:超过40%的受者患有皮肤癌(非糖尿病受者的平均年龄为53±13岁;糖尿病受者为49±8岁),超过10%患有非皮肤癌(非糖尿病受者的平均年龄为53±16岁;糖尿病受者为46±9岁),超过30%患有CVD(非糖尿病受者的平均年龄为53±15岁;糖尿病受者为47±9岁)。我们得出结论,长期移植受者的发病率和早期死亡率较高。随着短期结果的改善,需要更多地关注长期转归情况。

相似文献

引用本文的文献

本文引用的文献

4
Excerpts from the United States Renal Data System 2007 annual data report.美国肾脏数据系统2007年年报摘录。
Am J Kidney Dis. 2008 Jan;51(1 Suppl 1):S1-320. doi: 10.1053/j.ajkd.2007.11.001.
8
Prednisone-free maintenance immunosuppression-a 5-year experience.无泼尼松维持免疫抑制——5年经验
Am J Transplant. 2005 Oct;5(10):2473-8. doi: 10.1111/j.1600-6143.2005.01051.x.
10
A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results.
Transplantation. 2004 Dec 15;78(11):1653-60. doi: 10.1097/01.tp.0000144181.47045.fe.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验